Dermavant Is Committed to Fostering Unprecedented Change and Unparalleled Impact in Immuno-Dermatology

We're doing this by thinking differently, pushing the boundaries of science and partnering with providers in new ways — all with one goal: transforming the lives of millions of patients with skin diseases.

About Dermavant

A Passion for Science and a Commitment to Dermatology

Dermavant Sciences, a subsidiary of Roivant Sciences, is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant's focus is to develop therapies that have the potential to address unmet medical needs while driving greater efficiency in research and clinical development.

The company’s medical dermatology pipeline includes earlier-development and late-stage product candidates as well as a commercialized product candidates that target specific unmet needs in two of the largest growing immuno-dermatology markets — plaque psoriasis and atopic dermatitis — as well as other immunological and inflammatory diseases.

Dermavant launched its first product, VTAMA® (tapinarof) cream, 1%, for the topical treatment of plaque psoriasis in adults in 2022. Dermavant is also developing VTAMA cream for the treatment of atopic dermatitis in adults and children as young as 2 years old. Atopic dermatitis, the most common type of eczema, affects more than 9.6 million children and 16.5 million adults in the United States.

IMPORTANT SAFETY INFORMATION

Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.

Adverse Events: The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Executive Leadership Team

Todd Zavodnick  
Chief Executive Officer

Chris Chapman  
Chief Commercial Officer

Chris Van Tuyl  
Chief Legal Officer

Michael Swartzburg  
Chief Financial Officer

David Rubenstein  
Chief Scientific Officer

Philip Brown  
Chief Medical Officer

Paul Seaback  
Chief Technical Officer

Dermavant Has VTAMA Cream and Other Candidates in Development Addressing:

Plaque Psoriasis in Adults, Atopic Dermatitis and other Immunological and Inflammatory Diseases

<table>
<thead>
<tr>
<th>AVAILABLE PRODUCT</th>
<th>APPROVED INDICATION</th>
<th>STAGE OF DEVELOPMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>VTAMA® cream (DMVT-505)</td>
<td>A topical aryl hydrocarbon receptor (AhR) agonist</td>
<td>Plaque Psoriasis in Adults</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRODUCT CANDIDATE</th>
<th>POTENTIAL INDICATION</th>
<th>STAGE OF DEVELOPMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tapinarof (DMVT-505)</td>
<td>Atopic Dermatitis</td>
<td></td>
</tr>
<tr>
<td>DMVT-506</td>
<td>Immunological and Inflammatory Diseases</td>
<td></td>
</tr>
</tbody>
</table>